Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Withdrawn Not applicable Interventional

Dynamic Splinting for Excessive Pronation Following CVA

NCT00900692
View directory record Official record
Conditions
Pronation Contracture
Interventions
Dynasplint
Device
Lead sponsor
Dynasplint Systems, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 30, 2026, 11:37 AM EDT
Recruiting Not applicable Interventional

Improving Adherence to Chronic Disease Medication Regimens Among Patients With Recently Diagnosed Cancer

NCT07811258
View directory record Official record
Conditions
Cancer
Interventions
Medisafe Medication Management Program, Pharmacist-Led Medication Review
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VDOT for Monitoring Adherence to LTBI Treatment

NCT02641106
View directory record Official record
Conditions
Tuberculosis, Latent Tuberculosis Infection
Interventions
Video Directly Observed Therapy, In-Person DOT
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 30, 2026, 11:37 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Placebo
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
122
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 3 Interventional Results available

Celebrex In Acute Gouty Arthritis Study

NCT00549549
View directory record Official record
Conditions
Arthritis, Gouty
Interventions
Indomethacin, Celecoxib
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Glendale, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 11:37 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07280156
View directory record Official record
Conditions
Gout
Interventions
PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate
Biological · Drug · Other
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
26
States / cities
Glendale, Arizona • Little Rock, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

NCT00730405
View directory record Official record
Conditions
Onychomycosis
Interventions
Albaconazole 100mg, Albaconazole 200mg, Albaconazole 400mg, Placebo 400 mg
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 2 Interventional

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

NCT00317395
View directory record Official record
Conditions
Coronary Disease
Interventions
Otamixaban (XRP0673), unfractionated heparin, eptifibatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 1 Interventional Results available

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

NCT03343301
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
Interventions
Bemarituzumab, Modified FOLFOX6
Biological · Drug
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Tucson, Arizona • Greenbrae, California • Whittier, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

NCT00763815
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Not applicable Interventional

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Wasting Disease
Interventions
Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Not applicable Interventional Results available

Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens

NCT01653847
View directory record Official record
Conditions
End Stage Renal Failure With Renal Transplant
Interventions
Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Not applicable Interventional

Study Buddy (an ECA Oncology Trial Advisor) for Cancer Trials

NCT02742740
View directory record Official record
Conditions
Patient Satisfaction, Patient Compliance, Guideline Adherence
Interventions
Chemo Buddy
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 30, 2026, 11:37 AM EDT
Recruiting Not applicable Interventional

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

NCT06923397
View directory record Official record
Conditions
Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin, Sedentary Behavior
Interventions
Interrupted Sedentary Time Intervention
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Withdrawn No phase listed Observational

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

NCT02492360
View directory record Official record
Conditions
Peripheral Nervous System Diseases, Testicular Neoplasms
Interventions
Blood sample collection, Report of peripheral neuropathy after cisplatin therapy
Procedure · Behavioral
Lead sponsor
Costantine Albany
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 30, 2026, 11:37 AM EDT
Completed No phase listed Observational

Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients

NCT02535182
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Blood Draw
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

NCT00946192
View directory record Official record
Conditions
Exercise-related Amenorrhea
Interventions
Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 30, 2026, 11:37 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of COYA 302 for the Treatment of ALS

NCT07161999
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

NCT01963598
View directory record Official record
Conditions
Sarcopenia
Interventions
REGN1033 (SAR391786), placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Anniston, Alabama • Phoenix, Arizona • El Cajon, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT02481219
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
Device · Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 30, 2026, 11:37 AM EDT
Recruiting Phase 2 Interventional

Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

NCT07315165
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Interventions
Enteral Nutrition
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Withdrawn Phase 2 Interventional

Topical Steroids & Bacterial Decolonization for Radiation Dermatitis

NCT05505214
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Bacterial decolonization, Mometasone furoate 0.1% cream, Bacterial decolonization and Mometasone furoate 0.1% cream
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 30, 2026, 11:37 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

NCT04459416
View directory record Official record
Conditions
Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
Interventions
Acupuncture, opioid, Assessments
Other · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 11:37 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

NCT01777165
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ABT-719, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Danbury, Connecticut • Gainesville, Florida • Jacksonville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 30, 2026, 11:37 AM EDT